(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 6 May 2005 (06.05.2005)

PCT

(10) International Publication Number WO 2005/040125 A1

(51) International Patent Classification7: C07D 215/44, A61K 31/517

(21) International Application Number:

PCT/EP2004/011118

(22) International Filing Date: 5 October 2004 (05.10.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

03022647.6

6 October 2003 (06.10.2003)

- (71) Applicant (for all designated States except US): AXXIMA PHARMACEUTICALS AG [DE/DE]; Max-Lebsche-Platz 32, 81377 Munich (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HERGET, Thomas [DE/DE]; Alicenstr. 27, 64293 Darmstadt (DE).
- (74) Agent: ARTH, Hans-Lothar; Arth, Bucher & Kollegen, Am Klopferspitz 19 (IZB), 82152 Munich- Martinsried (DE).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS



HCMV AD 169 Plaque Reduction Assay

Control 1 and Control 2 served as control compounds.

(57) Abstract: The present invention relates to phenyl-quinazolinyl-amine derivatives and pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one of these derivatives and/or pharmaceutically salts thereof, as well as the use of these derivatives for the prophylaxis and/or treatment of herpesviral induced infections, including opportunistic infections, especially for the prophylaxis and/or treatment of infections and diseases induced by HCMV.